Endoscopic Papillectomy Versus Surgery for Ampullary Tumors: A Prospective Multicenter Cohort Study
Investigation of the Indications and Clinical Outcomes of Endoscopic Papillectomy Versus Surgery for Ampullary Tumors
The aim of this study is to compare the efficacy and safety of endoscopic treatment (endoscopic papillectomy [EP] with or without intraductal radiofrequency ablation [RFA]) and surgical treatment (transduodenal ampullectomy [TSA] and pancreatoduodenectomy [PD]) in patients with ampullary tumors (ampullary adenoma and early ampullary carcinoma), focusing on residual disease, recurrence, postoperative complications, and overall costs.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a multicenter, two-arm, prospective cohort study. The diagnosis of ampullary adenoma must be confirmed by biopsy.
The endoscopic treatment group receives EP; patients without intraductal extension receive EP alone, while patients with intraductal extension receive additional RFA in the same or a subsequent session. The surgical treatment group receives TSA or PD. Patients are followed up at 3, 6, and 12 months after the initial treatment, then annually for at least 5 years, with side-viewing duodenoscopy, targeted biopsy, and CT assessment. To control confounding between the two groups, propensity score matching and inverse probability of treatment weighting will be applied.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Zhen Li, MD
- Numéro de téléphone: 18560086106
- E-mail: qilulizhen@sdu.edu.cn
Sauvegarde des contacts de l'étude
- Nom: Ning Zhong, MD
- Numéro de téléphone: 18560086096
- E-mail: zhongning@email.sdu.edu.cn
Lieux d'étude
-
-
Shandong
-
Jinan, Shandong, Chine, 250012
- Qilu Hospital of Shandong University
-
Contact:
- Zhen Li
- Numéro de téléphone: 18560086106
- E-mail: qilulizhen@sdu.edu.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Adult patients with histologically confirmed ampullary adenoma or early ampullary carcinoma (Tis/T1) without invasion into the duodenal muscularis propria, staged M0/N0 by EUS , MRCP and CT , with intraductal tumor extension ≤ 20 mm on EUS, MRCP, or IDUS, undergoing endoscopic papillectomy or surgery.
La description
Inclusion Criteria:
- Patients aged ≥18 years
- Patients with histologically confirmed ampullary adenoma or early ampullary carcinoma (Tis/T1) based on endoscopic biopsy (i.e., without tumor invasion into the duodenal muscularis propria).
- Preoperative staging by endoscopic ultrasound (EUS) , magnetic resonance cholangiopancreatography (MRCP) or computed tomography (CT) showing no distant metastasis (M0) and no lymph node metastasis (N0).
- Intraductal tumor extension (ITE) ≤ 20 mm assessed by EUS, MRCP or Intraductal ultrasound (IDUS ).
- Planned to undergo EP, with or without intraductal RFA, or surgical treatment (TSA or PD).
- Patients who provide written informed consent.
Exclusion Criteria:
- Patients unable to tolerate general anesthesia or surgery.
- Ectopic duodenal papilla.
- Contraindications to endoscopic procedures (e.g., severe esophageal stenosis, gastric outlet obstruction, or other conditions precluding endoscopic access to the papilla).
- Major upper abdominal surgery or previous biliary surgery history.
- Uncorrectable coagulopathy (INR > 1.5) or thrombocytopenia (platelet count < 50,000/μL), or inability to withhold antithrombotic (anticoagulant or antiplatelet) therapy for the planned endoscopic or surgical procedure..
- Pregnant or lactating women.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Endoscopic treatment group
Patients undergoing EP with or without RFA. |
Endoscopic papillectomy (EP); EP combined with intraductal RFA for lesions with intraductal tumor extension. |
|
Surgical treatment group
Patients undergoing surgical treatment. |
TSA or PD |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Recurrence rate at 12 months
Délai: At 12 months after the initial treatment
|
Recurrence confirmed by endoscopic biopsy after an interval ≥ 3 months from the end of treatment, assessed at the 12-month follow-up. |
At 12 months after the initial treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
R0 resection rate
Délai: Periprocedural
|
Proportion of patients with complete resection achieved at the first endoscopic or surgical intervention and confirmed by histology (negative margins). |
Periprocedural
|
|
Procedure-related adverse event rate
Délai: Up to 90 days after the initial treatment
|
Proportion of patients who experienced at least one adverse event attributable to the initial endoscopic or surgical procedure within 30 days after the procedure, irrespective of severity. |
Up to 90 days after the initial treatment
|
|
Recurrence rate at 6 months
Délai: At 6 months after the initial treatment
|
Recurrence confirmed by endoscopic biopsy after an interval ≥ 3 months from the end of treatment, assessed at the 6-month follow-up. |
At 6 months after the initial treatment
|
|
Residual lesion rate
Délai: Up to 3 months after the initial treatment
|
Presence of residual adenoma tissue at the next endoscopy after treatment. |
Up to 3 months after the initial treatment
|
|
Clinical success rate
Délai: Up to 5 years after the initial treatment
|
Proportion of patients who achieved complete excision of the lesion (regardless of the number of procedures) with no histologically confirmed adenoma regrowth, no evidence of invasive cancer, and without the need for surgical resection, during follow-up up to 5 years after the initial treatment. |
Up to 5 years after the initial treatment
|
|
Endoscopic treatment failure rate
Délai: Up to 12 months after the initial treatment
|
Inability to completely resect the lesion endoscopically (regardless of the number of procedures), histopathologically invasive malignancy, or recurrence no longer amenable to endoscopic treatment. |
Up to 12 months after the initial treatment
|
|
Total number of readmissions within 12 months
Délai: Up to 12 months after the initial treatment
|
All readmissions due to disease-related symptoms (e.g., cholangitis, pancreatitis, obstructive jaundice) or treatment-related events (e.g., bleeding, perforation, anastomotic problems). |
Up to 12 months after the initial treatment
|
|
Technical success rate
Délai: Periprocedural
|
Proportion of patients in whom the planned procedure was completed as intended. |
Periprocedural
|
|
Total treatment cost
Délai: Up to 12 months after the initial treatment
|
All direct medical costs from admission to 12 months after the initial treatment (including procedure, anesthesia, hospitalization, medication, examinations, and readmission costs). |
Up to 12 months after the initial treatment
|
|
Index hospitalization length of stay
Délai: Periprocedural
|
Number of calendar days from the date of admission for the initial treatment to the date of discharge for the initial treatment,including the day of admission |
Periprocedural
|
|
Total length of stay within 12 months
Délai: Up to 12 months after the initial treatment
|
Total number of calendar days spent in hospital within 12 months after the initial treatment, including the index hospitalization and all readmissions due to disease-related symptoms or treatment-related events. |
Up to 12 months after the initial treatment
|
|
Postprocedural pancreatitis rate
Délai: Up to 90 days after the initial treatment
|
Defined by two of three criteria: characteristic abdominal pain; amylase or lipase > 3× upper limit of normal; imaging features of pancreatitis; severity graded mild / moderate / severe per protocol. |
Up to 90 days after the initial treatment
|
|
Postprocedural bleeding rate
Délai: Up to 90 days after the initial treatment
|
Proportion of patients with clinically significant post-procedural bleeding within 30 days after the procedure, defined as any of the following after achieving primary haemostasis: overt bleeding symptoms (hematemesis, melena, hematochezia, or blood aspirated via nasogastric tube); haemodynamic instability attributable to bleeding; a decrease in haemoglobin greater than 2 g/dL; or direct endoscopic evidence of bleeding from the papillectomy site. |
Up to 90 days after the initial treatment
|
|
Postprocedural perforation rate
Délai: Up to 90 days after the initial treatment
|
Direct visualization of a transmural defect during endoscopy, or radiographic evidence of extraluminal free air on abdominal CT or plain radiograph. |
Up to 90 days after the initial treatment
|
|
Postprocedural cholangitis rate
Délai: Up to 90 days after the initial treatment
|
New onset temperature >38 °C for more than 24 hours combined with cholestasis. Severity will be graded separately according to the TG18 severity classification (Grade I / II / III) and reported descriptively. |
Up to 90 days after the initial treatment
|
|
Cumulative recurrence rate
Délai: Through study completion, an average of 5 years
|
Cumulative recurrence during annual follow-up up to 5 years |
Through study completion, an average of 5 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Zhen Li, MD, Qilu Hospital of Shandong University
Publications et liens utiles
Publications générales
- Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027. No abstract available.
- Vanbiervliet G, Strijker M, Arvanitakis M, Aelvoet A, Arnelo U, Beyna T, Busch O, Deprez PH, Kunovsky L, Larghi A, Manes G, Moss A, Napoleon B, Nayar M, Perez-Cuadrado-Robles E, Seewald S, Barthet M, van Hooft JE. Endoscopic management of ampullary tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2021 Apr;53(4):429-448. doi: 10.1055/a-1397-3198. Epub 2021 Mar 16.
- Kiriyama S, Kozaka K, Takada T, Strasberg SM, Pitt HA, Gabata T, Hata J, Liau KH, Miura F, Horiguchi A, Liu KH, Su CH, Wada K, Jagannath P, Itoi T, Gouma DJ, Mori Y, Mukai S, Gimenez ME, Huang WS, Kim MH, Okamoto K, Belli G, Dervenis C, Chan ACW, Lau WY, Endo I, Gomi H, Yoshida M, Mayumi T, Baron TH, de Santibanes E, Teoh AYB, Hwang TL, Ker CG, Chen MF, Han HS, Yoon YS, Choi IS, Yoon DS, Higuchi R, Kitano S, Inomata M, Deziel DJ, Jonas E, Hirata K, Sumiyama Y, Inui K, Yamamoto M. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):17-30. doi: 10.1002/jhbp.512. Epub 2018 Jan 5.
- Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, Telford JJ, Leontiadis GI. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Am J Gastroenterol. 2022 Apr 1;117(4):542-558. doi: 10.14309/ajg.0000000000001627.
- Karam E, Hollenbach M, Ali EA, Auriemma F, Gulla A, Heise C, Regner S, Gaujoux S; on the Pancreas 2000 Research Group; Regimbeau JM, Kahler G, Seyfried S, Vaillant JC, De Ponthaud C, Sauvanet A, Birnbaum D, Regenet N, Truant S, Perez-Cuadrado-Robles E, Bruzzi M, Lupinacci RM, Brunel M, Belfiori G, Barbier L, Salame E, Souche FR, Schwarz L, Maggino L, Salvia R, Gagniere J, Del Chiaro M, Leung G, Hackert T, Kleemann T, Paik WH, Caca K, Dugic A, Muehldorfer S, Schumacher B, Albers D. Outcomes of rescue procedures in the management of locally recurrent ampullary tumors: A Pancreas 2000/EPC study. Surgery. 2023 May;173(5):1254-1262. doi: 10.1016/j.surg.2022.12.011. Epub 2023 Jan 13.
- Fritzsche JA, Fockens P, Barthet M, Bruno MJ, Carr-Locke DL, Costamagna G, Cote GA, Deprez PH, Giovannini M, Haber GB, Hawes RH, Hyun JJ, Itoi T, Iwasaki E, Kylanpaa L, Neuhaus H, Park JY, Reddy DN, Sakai A, Bourke MJ, Voermans RP. Expert consensus on endoscopic papillectomy using a Delphi process. Gastrointest Endosc. 2021 Oct;94(4):760-773.e18. doi: 10.1016/j.gie.2021.04.009. Epub 2021 Apr 19.
- Abe S, Sakai A, Masuda A, Miki M, Harada Y, Nagao K, Inomata N, Kohashi S, Uemura H, Masuda S, Ashina S, Gonda M, Yamakawa K, Tsujimae M, Yamada Y, Tanaka T, Kobayashi T, Nakano R, Shiomi H, Tsugawa D, Yanagimoto H, Ajiki T, Kanzawa M, Fukumoto T, Itoh T, Kodama Y. Advantage of endoscopic papillectomy for ampullary tumors as an alternative treatment for pancreatoduodenectomy. Sci Rep. 2022 Sep 7;12(1):15134. doi: 10.1038/s41598-022-19439-3.
- Hollenbach M, Heise C, Abou-Ali E, Gulla A, Auriemma F, Soares K, Leung G, Schattner MA, Jarnagin WR, Wang T, Caillol F, Giovannini M, Dahel Y, Hackert T, Paik WH, Zerbi A, Nappo G, Napoleon B, Arnelo U, Haraldsson E, Halimi A, Waldthaler A, Will U, Saadeh R, Masaryk V, van der Wiel SE, Bruno MJ, Perez-Cuadrado-Robles E, Deprez P, Sauvanet A, Bolm L, Keck T, Souche R, Fabre JM, Musquer N, Kahler G, Seyfried S, Petrone MC, Mariani A, Zaccari P, Belfiori G, Crippa S, Falconi M, Partelli S, Yilmaz B, Demir IE, Ceyhan GO, Satoi S, Regimbeau JM, Gagniere J, Repici A, Anderloni A, Vollmer C, Casciani F, Del Chiaro M, Oba A, Schulick RD, Berger A, Maggino L, Salvia R, Schemmer P, Wichmann D, Inoue Y, Dinis-Ribeiro M, Laranjo A, Libanio D, Kleemann T, Sandru V, Ilie M, Ahola R, Laukkarinen J, Schumacher B, Albers D, Curdia Goncalves T, Barbier L, Salame E, Weismuller TJ, Heling D, Alves A, Karam E, Regenet N, Dugic A, Muehldorfer S, Truant S, Caca K, Meier B, Miutescu BP, Tantau M, Birnbaum D, Miksch RC, Wedi E, Salzmann K, Bruzzi M, Lupinacci RM, David P, De Ponthaud C, Schmidt A, Regner S, Gaujoux S; ESAP study group. Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis. Gut. 2025 Feb 6;74(3):397-409. doi: 10.1136/gutjnl-2022-327996.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 2026SDU-QILU-6
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .